Moderately to Severely Active Crohn's Disease

DrugDrug NameDrug Description
DB00051AdalimumabAdalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor [A39984], [A39999]. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA [A39983]. This drug is frequently known as _Humira_. It is produced by recombinant DNA technology using a mammalian cell expression system. This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered doses [A39983]. A new biosimilar to adalimumab, named _adalimumab-adaz_, was approved by the FDA on October 31, 2018. This biosimilar is known as _Hyrimoz_, and is a trademark of Novartis AG [L4799].
DrugDrug NameTargetType
DB00051AdalimumabTumor necrosis factortarget
DrugDrug NamePhaseStatusCount
DB08904Certolizumab pegol3Completed1